AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Recruiting

Phase 1

Phase 2

AB-3028AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Sponsor:

Arsenal Biosciences, Inc.

Code:

NCT07285694

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AB-3028

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-14. This information was provided to ClinicalTrials.gov by Arsenal Biosciences, Inc. on 2026-01-12.